Creative Biostructure

Online Inquiry

Please enter "biostructure" as the verification code.

Mempro™ Liposome in Gene Therapy

Creative Biostructure has focused on the research and development of liposome technology in rencent years, which makes us to be the expert in this field. Creative Biostructure has established a magic Mempro™ Liposome platform with our scientific elites and advanced facilities. Liposomes are composed of small artificial spherical vesicles that can be constructed by various natural phospholipids and cholesterols. Liposomes are non-toxic and biocompatible nanoparticles that offer innumerable possibilities in that they can be easily designed and tailored to suit a specific application like gene therapy.

Figure 1. Delivery vectors for intracellular delivery of nucleic acids and properties of an engineered synthetic vector for gene therapy in the future. (S. Akhtar., 2006) Figure 1. Delivery vectors for intracellular delivery of nucleic acids and properties of an engineered synthetic vector for gene therapy in the future. (S. Akhtar., 2006)

The major purpose of gene therapy is to deliver genetic meterails such as DNA, RNA, and antisense sequences to living cells, which could alleviate symptoms or prevent diseases. The major applications of liposomes in gene therapy include gene replacement, addition of genes in order to produce natural toxins or sensitizing cells for other treatments, and over-expression of highly immunogenic genes for immune self-attack. A variety of diseases which could benefit from gene therapy by repairation of mutated genes and increasement of the body’s response, such as cystic fibrosis, sickle cell anemia, immune system deficiencies, transmissible viral diseases (HIV, hepatitis), neurological diseases (Parkinson’s disease and Alzheimer’s disease), and hemophilia. It has been characterized that cationic liposomes are able to electrostatically interact with anionic DNA, RNA, and peptides/proteins, and assembled into particles which are small and stable to maintain increased transfection efficiencies. Applying Mempro™ Liposome Technology in gene therapy has various advantages including:

  1. The size of to be delivered nucleic acids are not limited.
  2. To produce liposome complexes which deliver therapeutics on a large scale in a low cost and easy way.
  3. Using colloidal or surface properties, we are able to target liposome complexes.
  4. Liposomes have little immunogenicity.

In order to target liposome to a specific site, ligands should be added by ionic interactions or by covalent attachments. Ligands, which bind to specific sites on a target protein, are signal-triggering molecules. Typically polyethylene glycol-conjugated (PEGylated) lipids are used to prepare noninteracting liposomes; however, normal liposomes can become sterically stable by incubation with PEG-lipid micelles making them interact with DNA.

Creative Biostructure has overcome the key obstacles to ensure the continued functionality of encapsulated genetic materials by designing novel liposomes to not only lower the susceptibility of DNA and RNA to nucleases but also have a long shelf life. For the purpose of increasing the cellular uptake of genetic material encapsulated within liposomes, Creative Biostructure has modified liposomes which tagged with viral envelope proteins in order to recognize and attach to the target cell membranes. The subsequent liposome fusion with the target cells will result in high therapeutic delivery.

Besides gene therapy, Creative Biostructure has also applied Mempro™ Liposome platform in a broad range of fields including food industry, cosmetics, drug delivery and cancer therapy, etc. We promise to provide you the best products and first-class services based on Mempro™ Liposome Technology. Please feel free to contact us for a detailed quote.

D. A. Balazs and W. T. Godbey. (2011). Liposomes for Use in Gene Delivery. Journal of Drug Delivery, 2011: 326497.
S Mali. (2013). Delivery systems for gene therapy. Indian J Hum Genet., 19(1): 3–8.
S. Akhtar. (2006). Non-viral cancer gene therapy: Beyond delivery. Gene Therapy, 13: 739-740.

Related Sections